<DOC>
	<DOCNO>NCT01982162</DOCNO>
	<brief_summary>Cross-sectional study characterize cohort child asthma healthy control term clinical feature , physiological measurement non-invasive measurement biomarkers develop phenotype handprints child severe asthma</brief_summary>
	<brief_title>Longitudinal Assessment Children With Severe Asthma Severe Pre-school Wheeze</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Parent / guardian must able give write informed consent prior participation study , include ability comply requirement restriction list consent form . Informed consent must obtain prior undertake study procedure . 2 . Assent obtain child study appropriate . 3 . Male female subject age 1 17 year inclusive screening . 4 . The parent / guardian , appropriate child must able read , comprehend , write sufficient level complete study related material . 5 . Subjects allow enrol study take part study . However , Permission Scientific Board must obtain enrol allow continue participation subject enrol another study . 1 . As result medical interview , physical examination screen investigation physician responsible considers child unfit study . 2 . The subject history drug allergy , , opinion responsable physician , contraindicate participation . 3 . Subject female pregnant lactate 6 week post partum 6 week cessation breast feeding . If woman subsequently find pregnant time assessment data assessment include analyse 4 . The child participate within 3 month first dose study use new molecular entity , first dose study investigate drug participate within three month study invasive procedure . Any UBIOPRED assessment defer 3 month first dose invasive procedure . Permission Scientific Board must obtain enroll allow continue participation child enrol another study . 5 . Those , opinion investigator , risk noncompliance study procedure . 6 . Prematurity â‰¤35 week gestation 7 . The child change asthma medication within 4 week screen assessment ( except use Symbicort maintenance reliever therapy ( SMART ) regime ) ( assessment defer ) 8 . History current evidence upper low respiratory infection symptom ( include common cold ) within 2 week baseline assessment ( assessment defer ) . 9 . The child severe exacerbation ( require ER attendance hospital admission and/or course high dose OCS least 3 day duration ) within 4 week baseline assessment ( assessment defer ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Sputum</keyword>
	<keyword>Clinical cohort</keyword>
	<keyword>Smokers</keyword>
	<keyword>Asthma</keyword>
	<keyword>Biopsies</keyword>
	<keyword>Severe asthma</keyword>
	<keyword>Collaborative research</keyword>
	<keyword>Phenotyping</keyword>
	<keyword>Lipidomics</keyword>
	<keyword>Transcriptomics</keyword>
	<keyword>Proteomics</keyword>
	<keyword>Paediatric cohort</keyword>
	<keyword>Systems Biology</keyword>
</DOC>